Bristol-Myers Squibb Company (BMY) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Bristol-Myers Squibb Company (BMY) is Moderate Outperform.

The composite score behind that read is +0.27, weighing +0.34 of bullish evidence against -0.15 bearish.

Bristol-Myers Squibb Company last closed at $59.12, -0.77% on the session.

Against the IVW growth benchmark the position is -1.57% over the forecast window.

The read is built from 15 underlying insights — 12 bullish and 3 bearish.

Agreement across those insights is 80%.

Bristol-Myers Squibb Company has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Bristol-Myers Squibb Company in the 70th percentile on valuation and the 92nd percentile on return on equity, where 100 is best.

Bristol-Myers Squibb Company is classified under Health Care / Pharmaceuticals, with a market capitalisation of $121.70B.

StockMap tracks Bristol-Myers Squibb Company as the 8th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Bristol-Myers Squibb Company ranks 4th of 151 in the group, against a group median of -0.08.